Skip to main content

Drugs

Monoclonal antibody model

10-23-2023 | Type 1 diabetes | News

Teplizumab may PROTECT β-cell function in youth with newly diagnosed type 1 diabetes

Early treatment with the anti-CD3 monoclonal antibody teplizumab may help to preserve β-cell function in children and adolescents with newly diagnosed type 1 diabetes, results of the phase 3 PROTECT study show.

10-18-2023 | Type 1 diabetes | News

Automated insulin delivery benefits type 1 diabetes individuals at high hypoglycemia risk

Automated insulin delivery reduces hypoglycemia in people with type 1 diabetes at increased risk, improving their time spent in target glucose range.

10-05-2023 | Type 2 diabetes | News

ONWARDS 5: Weekly insulin icodec with app shows real-world promise for type 2 diabetes

Result from ONWARDS 5 trial show weekly insulin icodec plus a dosing app offers greater reductions in glycated hemoglobin than daily basal insulin analogs for type 2 diabetes.

10-04-2023 | Hyperglycemia | News

High incidence of alpelisib‐associated hyperglycemia in routine care

A retrospective analysis has found a significantly higher incidence of hyperglycemia among breast cancer patients treated with alpelisib in standard care than on clinical trials.

09-12-2023 | Type 1 diabetes | News

Preservation of β-cell function with teplizumab in type 1 diabetes confirmed

Teplizumab consistently preserves the function of β-cells in people with type 1 diabetes as measured by higher C-peptide levels at 1 and 2 years post-treatment.

09-04-2023 | Type 2 diabetes | News

New model predicts kidney disease progression risk in type 2 diabetes

Novel model for risk prediction of kidney disease progression and efficacy of SGLT2 inhibition in patients with type 2 diabetes.

08-31-2023 | Type 2 diabetes | News

Pragmatic trial suggests best cardioprotective agents for type 2 diabetes

SGLT2 inhibitors and GLP-1 receptor agonists appear to offer the best protection against major adverse cardiovascular events in people with type 2 diabetes.

07-20-2023 | Type 2 diabetes | News

Triple agonist shows promise for both glycemic and weight control

Treating people with type 2 diabetes with the triple agonist retatrutide shows promising improvements in both glycemic control and reduction in obesity.